Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nasdaq Biotechnology Ishares ETF (NQ: IBB )

140.71 +2.75 (+1.99%)
Streaming Delayed Price Updated: 12:07 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nasdaq Biotechnology Ishares ETF

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
CPI Data Sparks Rally in Biotech Stocks
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Smalls And Mids Bios Try To Take The Lead While 2 Stocks Are On Watch For Pullback Entries
What an interesting week it was! It was about time, but the IWM finally broke out. I know it's lagging, so why do I like this breakout better? Because it's different. 
Via Talk Markets
Market Tries To Read Between The Lines
We have heard many discussions on whether small caps, like the Russell 2000 index really matter for the market. Do we care about the small caps? Is there a correction coming in large caps? 
Via Talk Markets
TSLA Hit Our Target - Here’s What’s Next
We’ll look at another big mover right now: precious metals. They still look good after Fed Chair Jerome Powell tried to talk down rate cuts today. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Big Brother Biotechnology Sector Revives
IBB sits just below the 200-WMA. Plus, he is in the middle of the weekly channel range. Furthermore, back in May, IBB handily cleared above the 50-WMA. 
Via Talk Markets
Weekly Visit With The Economy
Via Talk Markets
Topics Economy
Exposures Economy
Can Momentum Build In Small Caps?
IWM has not cleared the Bollinger Band or zero line in Leadership since 2023. Hence, until we see some real Leadership IWM is rangebound. 
Via Talk Markets
Quarterly & Long-Term Portfolios For The Win
What a day for Meta! I was planning to add to my position, but the volume was too low. I would have been shaken out of most of it for the swing before it could become this position trade. 
Via Talk Markets
3 Highly Rated Biotech Stocks for Your July Buy List
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. 
Via InvestorPlace
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
Tesla And Tech Are Still Taking The Bulls Higher
While we’ve seen some compelling signs that the market is ready for new leadership, tech is still presenting problems for the bears. 
Via Talk Markets
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged. 
Via Benzinga
Topics ETFs
U.S. Centric Indicators
The big takeaway is that the public does not see a top in sight and is buying at what could be record highs, at least for a while. 
Via Talk Markets
Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich
These three biotech stocks to buy carry risks but may appeal to speculative investors with time and patience. 
Via InvestorPlace
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. 
Via InvestorPlace
One Day Doth Not A Sector Rotation Make
IWM remains an underperformer to the benchmark. Real Motion shows a bit of a bearish divergence. Let’s compare this to Nvidia 
Via Talk Markets
Tech Is Consolidating And The Market’s Seeking New Leadership
The tape tells the tale, just like it always does: The tech sector is clearly in consolidation mode right now. 
Via Talk Markets
Want to Earn More in the Stock Market With Less Effort? Try This Simple Strategy
You don't need to be a stock market expert to earn above-average returns. 
Via The Motley Fool
Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?
Wall Street is experiencing a subdued and low volatility trading day Friday, despite the session coinciding with the “triple witching” day, with over $5.1 trillion of notional options exposure... 
Via Benzinga
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. 
Via MarketBeat
Exposures Product Safety
Weekly Update - Sunday, June 16
Today, I want to get right down to the technical analysis with some actionable plans. It should not come as a surprise to see the indices diverge even further than where they have been over the last... 
Via Talk Markets
Thoughts For Thursday: Tech Still Leading
The stock market continued to pull higher Wednesday with the biggest points gained in the Nasdaq Composite. Tech is still the big leader. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Pay No Attention To That Tran Behind The Curtain?
For the sake of redundancy and in case you are living under a rock and just came out to read my Daily, Nvidia (NVDA) and its ginormous beat on revenues, gave the market new life. 
Via Talk Markets
Why the Rest of 2024 Could Be Good for Investing in Biotech Stocks
Investors have been ignoring biotech stocks for far too long. Here's why they could start to heat up in 2024. 
Via InvestorPlace
Large Cap Biopharmaceuticals Performance
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
For Biotech Stocks To Move Higher, This Must Move Lower
While biotechs have significantly lagged behind the broader market, there is reason to be optimistic once inflation-related volatility subsides. IBB and XBI present good vehicles for biotech exposure. 
Via Talk Markets
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. 
Via MarketBeat
Topics ETFs
Consumer Spending - Single Most Driving Force
The choices we make as consumers collectively shape the economic landscape, and our spending patterns influence the well-being of our communities and the nation. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.